改良型组织工程血管移植物的合理设计：确定最佳细胞剂量和孵育时间。
Rational design of an improved tissue-engineered vascular graft: determining the optimal cell dose and incubation time.
作者信息
Lee Yong-Ung, Mahler Nathan, Best Cameron A, Tara Shuhei, Sugiura Tadahisa, Lee Avione Y, Yi Tai, Hibino Narutoshi, Shinoka Toshiharu, Breuer Christopher
机构信息
Tissue Engineering Program, The Research Institute at Nationwide Children's Hospital, 700 Children's Drive - WB4151, Columbus, OH 43205-2664, USA.
出版信息
Regen Med. 2016 Mar;11(2):159-67. doi: 10.2217/rme.15.85. Epub 2016 Feb 29.
Abstract
AIM
We investigated the effect of cell seeding dose and incubation time on tissue-engineered vascular graft (TEVG) patency.
MATERIALS & METHODS: Various doses of bone marrow-derived mononuclear cells (BM-MNCs) were seeded onto TEVGs, incubated for 0 or 12 h, and implanted in C57BL/6 mice. Different doses of human BM-MNCs were seeded onto TEVGs and measured for cell attachment.
RESULTS
The incubation time showed no significant effect on TEVG patency. However, TEVG patency was significantly increased in a dose-dependent manner. In the human graft, more bone marrow used for seeding resulted in increased cell attachment in a dose-dependent manner.
CONCLUSION
Increasing the BM-MNC dose and reducing incubation time is a viable strategy for improving the performance and utility of the graft.
摘要
目的
我们研究了细胞接种剂量和孵育时间对组织工程血管移植物（TEVG）通畅性的影响。
材料与方法
将不同剂量的骨髓来源单核细胞（BM-MNCs）接种到TEVGs上，孵育0小时或12小时，然后植入C57BL/6小鼠体内。将不同剂量的人BM-MNCs接种到TEVGs上并测量细胞附着情况。
结果
孵育时间对TEVG通畅性无显著影响。然而，TEVG通畅性以剂量依赖方式显著增加。在人移植物中，用于接种的骨髓越多，细胞附着以剂量依赖方式增加。
结论
增加BM-MNC剂量并缩短孵育时间是提高移植物性能和实用性的可行策略。
相似文献
1
Rational design of an improved tissue-engineered vascular graft: determining the optimal cell dose and incubation time.改良型组织工程血管移植物的合理设计：确定最佳细胞剂量和孵育时间。
Regen Med. 2016 Mar;11(2):159-67. doi: 10.2217/rme.15.85. Epub 2016 Feb 29.
2
Role of Bone Marrow Mononuclear Cell Seeding for Nanofiber Vascular Grafts.骨髓单个核细胞接种在纳米纤维血管移植物中的作用。
Tissue Eng Part A. 2018 Jan;24(1-2):135-144. doi: 10.1089/ten.TEA.2017.0044. Epub 2017 Jun 13.
3
Comparison of the biological equivalence of two methods for isolating bone marrow mononuclear cells for fabricating tissue-engineered vascular grafts.两种用于制备组织工程血管移植物的骨髓单个核细胞分离方法的生物学等效性比较。
Tissue Eng Part C Methods. 2015 Jun;21(6):597-604. doi: 10.1089/ten.TEC.2014.0442. Epub 2014 Dec 29.
4
Comparison of human bone marrow mononuclear cell isolation methods for creating tissue-engineered vascular grafts: novel filter system versus traditional density centrifugation method.比较用于构建组织工程血管移植物的人骨髓单核细胞分离方法：新型过滤系统与传统密度离心法。
Tissue Eng Part C Methods. 2011 Oct;17(10):993-8. doi: 10.1089/ten.TEC.2011.0110. Epub 2011 Jul 1.
5
Deconstructing the Tissue Engineered Vascular Graft: Evaluating Scaffold Pre-Wetting, Conditioned Media Incubation, and Determining the Optimal Mononuclear Cell Source.解构组织工程血管移植物：评估支架预湿润、条件培养基孵育并确定最佳单核细胞来源。
ACS Biomater Sci Eng. 2017;3(9):1972-1979. doi: 10.1021/acsbiomaterials.6b00123. Epub 2016 Aug 8.
6
Bone marrow-derived mononuclear cell seeded bioresorbable vascular graft improves acute graft patency by inhibiting thrombus formation via platelet adhesion.骨髓源单核细胞种植的生物可吸收血管移植物通过抑制血小板黏附来减少血栓形成，从而改善急性移植物通畅率。
Int J Cardiol. 2018 Sep 1;266:61-66. doi: 10.1016/j.ijcard.2018.01.059.
7
Evidence for in vivo growth potential and vascular remodeling of tissue-engineered artery.组织工程化动脉的体内生长潜力及血管重塑的证据。
Tissue Eng Part A. 2009 Apr;15(4):901-12. doi: 10.1089/ten.tea.2008.0172.
8
A novel strategy to engineer small-diameter vascular grafts from marrow-derived mesenchymal stem cells.一种从骨髓间充质干细胞构建小直径血管移植物的新策略。
Artif Organs. 2012 Jan;36(1):93-101. doi: 10.1111/j.1525-1594.2011.01231.x. Epub 2011 Jul 25.
9
Tissue Engineered Vascular Graft Recipient Interleukin 10 Status Is Critical for Preventing Thrombosis.组织工程血管移植物受体白细胞介素10状态对于预防血栓形成至关重要。
Adv Healthc Mater. 2020 Dec;9(24):e2001094. doi: 10.1002/adhm.202001094. Epub 2020 Oct 19.
10
Construction of an autologous tissue-engineered venous conduit from bone marrow-derived vascular cells: optimization of cell harvest and seeding techniques.利用骨髓来源的血管细胞构建自体组织工程静脉导管：细胞采集与接种技术的优化
J Pediatr Surg. 2007 Jan;42(1):198-202. doi: 10.1016/j.jpedsurg.2006.09.054.
引用本文的文献
1
Tissue Engineering of Vascular Grafts: A Case Report From Bench to Bedside and Back.血管移植物的组织工程：从基础到临床再到基础的案例报告。
Arterioscler Thromb Vasc Biol. 2023 Mar;43(3):399-409. doi: 10.1161/ATVBAHA.122.318236. Epub 2023 Jan 12.
2
Tissue engineered vascular grafts transform into autologous neovessels capable of native function and growth.组织工程血管移植物可转化为具有天然功能和生长能力的自体新血管。
Commun Med (Lond). 2022 Jan 10;2:3. doi: 10.1038/s43856-021-00063-7. eCollection 2022.
3
Current Progress in Vascular Engineering and Its Clinical Applications.血管工程学的当前进展及其临床应用。
Cells. 2022 Jan 31;11(3):493. doi: 10.3390/cells11030493.
4
CCL2 loaded microparticles promote acute patency in silk-based vascular grafts implanted in rat aortae.载趋化因子配体 2 的微颗粒促进了植入大鼠主动脉的丝素基血管移植物的急性通畅。
Acta Biomater. 2021 Nov;135:126-138. doi: 10.1016/j.actbio.2021.08.049. Epub 2021 Sep 5.
5
Review on Mechanical Support and Cell-Based Therapies for the Prevention and Recovery of the Failed Fontan-Kreutzer Circulation.关于机械支持和基于细胞的疗法预防和恢复Fontan-Kreutzer循环衰竭的综述。
Front Pediatr. 2021 Jan 26;8:627660. doi: 10.3389/fped.2020.627660. eCollection 2020.
6
Development of a Semi-Automated, Bulk Seeding Device for Large Animal Model Implantation of Tissue Engineered Vascular Grafts.用于大型动物模型植入组织工程血管移植物的半自动批量接种装置的开发。
Front Bioeng Biotechnol. 2020 Oct 23;8:597847. doi: 10.3389/fbioe.2020.597847. eCollection 2020.
7
Progressive Reinvention or Destination Lost? Half a Century of Cardiovascular Tissue Engineering.渐进式重塑还是迷失方向？心血管组织工程的半个世纪
Front Cardiovasc Med. 2020 Sep 9;7:159. doi: 10.3389/fcvm.2020.00159. eCollection 2020.
8
Spontaneous reversal of stenosis in tissue-engineered vascular grafts.组织工程血管移植物狭窄的自发逆转。
Sci Transl Med. 2020 Apr 1;12(537). doi: 10.1126/scitranslmed.aax6919.
9
In vivo implantation of 3-dimensional printed customized branched tissue engineered vascular graft in a porcine model.体内植入三维打印定制分支组织工程血管移植物在猪模型中的应用。
J Thorac Cardiovasc Surg. 2020 May;159(5):1971-1981.e1. doi: 10.1016/j.jtcvs.2019.09.138. Epub 2019 Oct 9.
10
Early natural history of neotissue formation in tissue-engineered vascular grafts in a murine model.组织工程血管移植物在小鼠模型中的新组织形成的早期自然史。
Regen Med. 2019 May;14(5):389-408. doi: 10.2217/rme-2018-0133. Epub 2019 Jun 10.
本文引用的文献
1
TGFβR1 inhibition blocks the formation of stenosis in tissue-engineered vascular grafts.转化生长因子β受体1抑制可阻断组织工程血管移植物中狭窄的形成。
J Am Coll Cardiol. 2015 Feb 10;65(5):512-4. doi: 10.1016/j.jacc.2014.08.057.
2
Comparison of the biological equivalence of two methods for isolating bone marrow mononuclear cells for fabricating tissue-engineered vascular grafts.两种用于制备组织工程血管移植物的骨髓单个核细胞分离方法的生物学等效性比较。
Tissue Eng Part C Methods. 2015 Jun;21(6):597-604. doi: 10.1089/ten.TEC.2014.0442. Epub 2014 Dec 29.
3
Implantation of inferior vena cava interposition graft in mouse model.在小鼠模型中植入下腔静脉间置移植物。
J Vis Exp. 2014 Jun 4(88):51632. doi: 10.3791/51632.
4
Comparison of a closed system to a standard open technique for preparing tissue-engineered vascular grafts.用于制备组织工程血管移植物的封闭系统与标准开放技术的比较。
Tissue Eng Part C Methods. 2015 Jan;21(1):88-93. doi: 10.1089/ten.TEC.2014.0160.
5
Biological and engineering design considerations for vascular tissue engineered blood vessels (TEBVs).用于血管组织工程血管（TEBVs）的生物学和工程设计考量
Curr Opin Chem Eng. 2014 Feb 1;3:83-90. doi: 10.1016/j.coche.2013.12.001.
6
First human use of an allogeneic tissue-engineered vascular graft for hemodialysis access.首例同种异体组织工程血管移植物用于血液透析通路的人体应用。
J Vasc Surg. 2014 Nov;60(5):1353-1357. doi: 10.1016/j.jvs.2013.08.018. Epub 2013 Oct 5.
7
Tissue-engineered vascular grafts for use in the treatment of congenital heart disease: from the bench to the clinic and back again.用于治疗先天性心脏病的组织工程血管移植物：从实验室到临床，再回到实验室。
Regen Med. 2012 May;7(3):409-19. doi: 10.2217/rme.12.12.
8
A critical role for macrophages in neovessel formation and the development of stenosis in tissue-engineered vascular grafts.巨噬细胞在组织工程血管移植物新生血管形成和狭窄发展中的关键作用。
FASEB J. 2011 Dec;25(12):4253-63. doi: 10.1096/fj.11-186585. Epub 2011 Aug 24.
9
Tissue-engineered vascular grafts form neovessels that arise from regeneration of the adjacent blood vessel.组织工程血管移植物形成新血管，这些新血管来源于相邻血管的再生。
FASEB J. 2011 Aug;25(8):2731-9. doi: 10.1096/fj.11-182246. Epub 2011 May 12.
10
Development of an operator-independent method for seeding tissue-engineered vascular grafts.开发一种操作人员独立的组织工程血管移植物种子方法。
Tissue Eng Part C Methods. 2011 Jul;17(7):731-6. doi: 10.1089/ten.TEC.2010.0581. Epub 2011 May 6.
Zotero 插件